Literature DB >> 24840578

Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.

Mahalakshmi Palani1, R Arunkumar, Arrambakam Janardhanam Vanisree.   

Abstract

Tropomyosin-related kinase family (NTRK1, NTRK2 and NTRK3) is well known to play an important role in the pathogenesis of brain tumour, which exhibit heterogeneity in its biological and clinical behaviour. However, the mechanism that regulates NTRKs in glioma is not well understood. The present study investigates the epigenetic status (methylation) of NTRKs and their expression in different grades of glioma. Promoter methylation and structural relationship of NTRKs was assessed using methylation-specific PCR followed by chromatin immunoprecipitation in brain tissue samples from 220 subjects with different grades of glioma. Control brain samples were also assessed similarly. Reverse transcriptase PCR was performed to analyse the expressions of NTRK mRNAs in the grades of glioma. In addition, the expression level of p75(NTR) protein was analysed using immunofluorescent technique in all of the samples. The overall percentage of NTRK3 gene methylation frequency with subsequent loss of mRNA expression was significantly higher in glioma compared with control samples (p < 0.05). No such significance was observed in other NTRK1 and NTRK2 genes. Further, mRNA expression pattern of NTRK1 and NTRK2 genes was found to be significantly higher in low grades as compared with high grades (HG) and control samples (p < 0.05). Survival rate of HG patients with negative expressions of NTRK1 and NTRK2 was poor than those with the positive expressions of both NTRK1 and NTRK2. Further, a significant correlation was observed with reduced expression of p75(NTR) and the expression pattern of NTRK family in glioma as compared with the control samples (p < 0.05). There exists a correlation between the expression of NTRK family and different grades of glioma with a significant suggestion that the promoter methylation does not play role in the regulation of these genes in glioma. Further, poor survival could be associated with NTRK mRNAs 1 and 2. Hence, NTRKs are potential probes for assessing the behaviour of different grades of glioma, which could also function as significant prognostic factors and thus deserve wider attention for an effective management of the grades.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24840578     DOI: 10.1007/s12017-014-8303-0

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  42 in total

Review 1.  Trk receptor tyrosine kinases: a bridge between cancer and neural development.

Authors:  A Nakagawara
Journal:  Cancer Lett       Date:  2001-08-28       Impact factor: 8.679

2.  Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma.

Authors:  Y Sakamoto; Y Kitajima; G Edakuni; E Sasatomi; M Mori; K Kitahara; K Miyazaki
Journal:  Oncol Rep       Date:  2001 May-Jun       Impact factor: 3.906

3.  Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population.

Authors:  Mahalakshmi Palani; Sabarinathan Devan; R Arunkumar; A J Vanisree
Journal:  Med Oncol       Date:  2010-09-16       Impact factor: 3.064

4.  Mitogenesis in glioblastoma multiforme cell lines: a role for NGF and its TrkA receptors.

Authors:  H S Singer; B Hansen; D Martinie; C L Karp
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors.

Authors:  M A Grotzer; A J Janss; K Fung; J A Biegel; L N Sutton; L B Rorke; H Zhao; A Cnaan; P C Phillips; V M Lee; J Q Trojanowski
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

6.  Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Zhongkui Li; Wayne A I Frederick; Wentao Yang; Kenji Yokoi; Douglas B Evans; James L Abbruzzese; Kenneth R Hess; Wei Zhang; Isaiah J Fidler; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

7.  Expression of neurotrophin receptor Trk-C in nevi and melanomas.

Authors:  Xiaowei Xu; Steven R Tahan; Terri L Pasha; Paul J Zhang
Journal:  J Cutan Pathol       Date:  2003-05       Impact factor: 1.587

Review 8.  Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification.

Authors:  William R Polkinghorn; Nancy J Tarbell
Journal:  Nat Clin Pract Oncol       Date:  2007-05

9.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  5 in total

1.  Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.

Authors:  Christine Jungk; Andreas Mock; Janina Exner; Christoph Geisenberger; Rolf Warta; David Capper; Amir Abdollahi; Sara Friauf; Bernd Lahrmann; Niels Grabe; Philipp Beckhove; Andreas von Deimling; Andreas Unterberg; Christel Herold-Mende
Journal:  BMC Med       Date:  2016-10-26       Impact factor: 8.775

2.  Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer.

Authors:  Zijian Chen; Zenghong Huang; Yanxin Luo; Qi Zou; Liangliang Bai; Guannan Tang; Xiaolin Wang; Guangwen Cao; Meijin Huang; Jun Xiang; Huichuan Yu
Journal:  J Transl Med       Date:  2021-02-16       Impact factor: 5.531

3.  NTRK3 gene fusion in an adult ganglioglioma: illustrative case.

Authors:  Sebastian Rubino; John Lynes; Paul McBride; Solmaz Sahebjam; Sepideh Mokhtari; Joaquim M Farinhas; Arie Perry; Robert Macaulay; Michael A Vogelbaum
Journal:  J Neurosurg Case Lessons       Date:  2022-01-31

4.  Comparative transcriptomics reveals similarities and differences between astrocytoma grades.

Authors:  Michael Seifert; Martin Garbe; Betty Friedrich; Michel Mittelbronn; Barbara Klink
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

5.  GFAPδ/GFAPα ratio directs astrocytoma gene expression towards a more malignant profile.

Authors:  Oscar M J A Stassen; Emma J van Bodegraven; Fabrizio Giuliani; Martina Moeton; Regina Kanski; Jacqueline A Sluijs; Miriam E van Strien; Willem Kamphuis; Pierre A J Robe; Elly M Hol
Journal:  Oncotarget       Date:  2017-10-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.